Search Results - "Bruscagnin, G"

The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases by GION, M, MIONE, R, NASCIMBEN, O, VALSECCHI, M, GATTI, C, LEON, A, BRUSCAGNIN, G

“…CA15.3 preoperatory serum levels have been determined in 667 patients with primary untreated breast cancer and in 193 controls. The relationships between…”
Get full text

Epidermal growth factor receptor in breast cancer. Comparison with non malignant breast tissue by DITTADI, R, DONISI, P. M, BRAZZALE, A, CAPPELLOZZA, L, BRUSCAGNIN, G, GION, M

“…Epidermal growth factor receptors were measured using a radioligand binding assay in membrane preparations from 67 cancer and 25 non-malignant tissues. The…”
Get full text

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial by Ambrosini, G, Balli, M, Garusi, G, Demicheli, R, Jirillo, A, Bonciarelli, G, Bruscagnin, G, Fila, G, Bumma, C, Lacroix, F, Buzzi, F, Di Costanzo, F, Padalino, D, Brugia, M, Calabresi, F, Natali, M, Cartei, G, Chiesa, G, Blasina, B, Ciambellotti, E, Moro, G, D'Aquino, S, Altavilla, G, Adamo, V, De Maria, D, Falchi, A M, Bertoncelli, P, Farris, A, Fiorentino, M, Fornasiero, A, Fosser, V, Daniele, O, Foggi, C M, Speranza, G B, Sartori, S, Camilluzzi, E, Gallo, L, Poggio, R, Secondo, V, Gambi, A, Grignani, F, Capodicasa, E, Lopez, M, Papaldo, P, Di Lauro, L, Vici, P, Marenco, G, Folco, U, Bonanni, F, Marsilio, P, Palazzotto, G, Di Carlo, A, Cusimano, M P, Pastorino, G, Puccetti, C, Giusto, M, Rausa, L, Gebbia, N, Palmeri, S, D'Alessandro, N, Saccani, F, Becchi, G, Schieppati, G, Spinelli, I, Tagliagambe, A, Tonato, M, Minotti, V, Ardia, A, Viaro, D, De Micheli, P, Zingali, G, Sacchetti, G, Intini, C

“…From February 1983 to January 1985, 497 patients with advanced breast cancer were randomly allocated to receive either epirubicin or doxorubicin in the…”
Get more information

PS2 in breast cancer - alternative or complementary tool to steroid receptor status? Evaluation of 446 cases by GION, M, MIONE, R, PAPPAGALLO, G. L, GATTI, C, NASCIMBEN, O, BARI, M, LEON, A. E, VINANTE, O, BRUSCAGNIN, G

“…The oestrogen induced pS2 protein was measured in the cytosol of 446 breast cancer samples by an immunoradiometric assay. The relationships between pS2 and…”
Get full text

Epidermal growth factor receptor in lung malignancies. Comparison between cancer and normal tissue by DITTADI, R, GION, M, PAGAN, V, BRAZZALE, A, DEL MASCHIO, O, BARGOSSI, A, BUSETTO, A, BRUSCAGNIN, G

“…Epidermal growth factor receptors (EGFr) were measured using a radioligand binding assay, in membrane preparations from 51 human non-small cell lung cancers…”
Get full text

Radioligand binding assay of epidermal growth factor receptor: causes of variability and standardization of the assay by Dittadi, R, Gion, M, Brazzale, A, Bruscagnin, G

“…Although experimental evidence indicates a probable role of epidermal growth factor receptor (EGFr) in clinical oncology, no standardized method for its…”
Get more information

Cost/effectiveness ratio of carcinoembryonic antigen--importance of adequacy of routine requests of tumor markers by Gion, M, Rampazzo, A, Mione, R, Bruscagnin, G

“…Since 1987 we have been evaluating the cost/effectiveness ratio of tumor markers using carcinoembryonic antigen (CEA) as a leading indicator. Preliminary to…”
Get more information

A new approach to tumour marker assessment by perioperative determination in breast and colorectal cancer by Gion, M, Ruggeri, G, Mione, R, Marconato, R, Casella, C, Nosadini, A, Simoncini, E, Belloli, S, Dal Zennaro, E, Bruscagnin, G

“…Preoperative serum tumour markers are currently classified as positive or negative according to a predetermined cut-off point. In the present study we examined…”
Get more information

Evaluation of a new IRMA method for the determination of neuron specific enolase by Mione, R, Bombardieri, E, Gion, M, Gatti, C, Bruscagnin, G

Get more information

Biochemical parameters in the cytosol of breast cancer by Dittadi, R, Mione, R, Gion, M, Leon, A, Bruscagnin, G

Get more information

Tumor-associated trypsin inhibitor (TATI) in primary esophageal carcinoma by Gion, M, Mione, R, Tremolada, C, Dalla Palma, P, Ruol, A, Dittadi, R, Leon, A, Nosadini, A, Castoro, C, Bruscagnin, G

“…Esophageal carcinoma has a catastrophic clinical course with a very low 5 year survival rate of 5%. A circulating tumor marker with good specificity and…”
Get more information

Tumor markers in serum of patients with primary squamous cell carcinoma of the esophagus by Gion, M, Tremolada, C, Mione, R, della Palma, P, Dittadi, R, Zari, C, Nosadini, A, Castoro, C, Ruol, A, Peracchia, A

“…Serum levels of several tumor markers were studied in 96 patients with untreated primary squamous cell carcinoma of the esophagus. Three markers specific for…”
Get more information

Tumor markers in squamous cell carcinoma of esophagus: immunometric assay in cytosol and membrane fraction by Gion, M, Tremolada, C, Mione, R, Dittadi, R, Della Palma, P, Castoro, C, Ruol, A, Nosadini, A, Peracchia, A, Bruscagnin, G

“…Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), ferritin, and the monoclonal antibody-detected tumor-associated antigens CA19.9 and CA50 were…”
Get more information

Immunoprecipitation method for a radioligand binding assay of epidermal growth factor receptor by Dittadi, R, Gion, M, Brazzale, A, Bruscagnin, G

Get more information

Estrogen and progesterone receptors in breast carcinoma and in nonmalignant breast tissue by Gion, M, Mione, R, Dittadi, R, Griggio, L, Munegato, G, Valescchi, M, Del Maschio, O, Fasan, S, Bruscagnin, G

“…Since 1983 we have studied the relationship, in the same patient, between receptor status in breast carcinoma and in nonmalignant breast tissue. Fifty patients…”
Get more information

Carcinoembryonic antigen, ferritin, tissue polypeptide antigen, and CA15/3 in breast cancer: relationship between carcinoma and normal breast tissue by Gion, M, Mione, R, Dittadi, R, Griggio, L, Munegato, G, Valsecchi, M, Del Maschio, O, Bruscagnin, G

“…The study of tumor markers in breast cancer tissue may supply information on the tumor's biological features and its clinical behaviour. Forty-nine primary…”
Get more information

Perioperatory kinetic evaluation of tumor markers in breast and colorectal carcinoma by Gion, M, Ruggeri, G, Marconato, R, Casella, C, Nosadini, A, Laffranchini, G, Mione, R, Belloli, S, Bruscagnin, G

Get more information

A mucinous-like carcinoma-associated antigen (MCA) in the tissue and blood of patients with primary breast cancer by Bombardieri, E, Gion, M, Mione, R, Dittadi, R, Bruscagnin, G, Buraggi, G

“…The monoclonal antibody (MAb) b12 raised against human breast cancer cell lines was found to identify an epitope of a mucinous-like carcinoma associated…”
Get more information

Tissue polypeptide antigen in breast cancer cytosol: a new effective prognostic indicator by Gion, M, Mione, R, Pappagallo, G L, Gatti, C, Nascimben, O, Brandes, A, Vinante, O, Bruscagnin, G

“…Since 1982 we have been evaluating oestrogen and progesterone receptors (PgR), cathepsin D and the cytosolic levels of the tumour marker, tissue polypeptide…”
Get more information

Carcinoembryonic antigen, ferritin, and tissue polypeptide antigen in serum and tissue. Relationship with the receptor content in breast carcinoma by Gion, M, Mione, R, Dittadi, R, Fasan, S, Pallini, A, Bruscagnin, G

“…In 225 primary breast carcinomas the concentrations of carcinoembryonic antigen (CEA), ferritin, and tissue polypeptide antigen (TPA) were determined by…”
Get more information